Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

J. Ryan, Charles; R. Smith, Matthew; S. de Bono, Johann; Molina, Arturo; J. Logothetis, Christopher; de Souza, Paul; Fizazi, Karim; N. Mainwaring, Paul; M. Piulats, Josep; Ng, Siobhan; Carles, Joan; F.A. Mulders, Peter; Basch, Ethan; J. Small, Eric; Saad, Fred; Schrijvers, Dirk; Van Poppel, Hendrik; D. Mukherjee, Som; Suttmann, H.; R. Gerritsen, Winald; W. Flaig, Thomas; J. George, Daniel; Y. Yu, Evan; Efstathiou, Eleni; J. Pantuck, Allan; Winquist, Eric; S. Higano, Celestia; Taplin, Mary-Ellen; Park, Youn; Kheoh, Thian; W. Griffin, Thomas; I. Scher, Howard; E. Rathkopf, Dana

doi:10.1056/nejmoa1209096

Public

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Published in New England Journal of Medicine • Dec 10, 2012

Authors:

Charles J. Ryan

Matthew R. Smith

Johann S. de Bono

Abstract

BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy. METHODS: In this double-blind study, we ...

Subject

Prednisone

Medicine

Abiraterone acetate

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!